Agenus Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for AGEN, updated each market day.
AGEN AI Sentiment
AI predicts Agenus Inc. stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Agenus Inc.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Sector
Exchange
Market Cap
$170,872,675
Cap Tier
Employees
81
Headquarters
LEXINGTON, MA
Listed Since
Feb. 4, 2000
Website
AGEN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
AGEN Volatility
Agenus Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
